5'-DFUR chemoprophylaxis in superficial bladder cancer. Kanagawa Urology 5'-DFUR Study Group

5'-DFUR chemoprophylaxis in superficial bladder cancer. Kanagawa Urology 5'-DFUR Study Group

5'-Deoxy-5-fluorouridine (5'-DFUR), an oral fluorinated pyrimidine carbamate, is widely used in patients with gastrointestinal and breast cancers because of its effectiveness. However, in bladder cancer, response rates have only been reported in Phase II clinical trials. Therefore, we cond...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 46(2000), 8 vom: 01. Aug., Seite 525-30
1. Verfasser: Kubota, Y (VerfasserIn)
Weitere Verfasser: Noguchi, S, Masuda, M, Hosaka, M, Noguchi, K, Sasaki, K, Miura, T, Ikeda, I, Kondo, I, Senga, Y, Moriyama, M, Fukushima, S, Ebato, T, Fukuda, M, Kitami, K, Fukuoka, H, Sato, K, Hirokawa, M, Chiba, K, Kanno, H, Miyai, K
Format: Aufsatz
Sprache:Japanese
Veröffentlicht: 2000
Zugriff auf das übergeordnete Werk:Hinyokika kiyo. Acta urologica Japonica
Schlagworte:Clinical Trial English Abstract Journal Article Multicenter Study Randomized Controlled Trial Antimetabolites, Antineoplastic Floxuridine 039LU44I5M doxifluridine V1JK16Y2JP
LEADER 01000naa a22002652 4500
001 NLM109389255
003 DE-627
005 20231222151231.0
007 tu
008 231222s2000 xx ||||| 00| ||jpn c
028 5 2 |a pubmed24n0365.xml 
035 |a (DE-627)NLM109389255 
035 |a (NLM)11019370 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a jpn 
100 1 |a Kubota, Y  |e verfasserin  |4 aut 
245 1 0 |a 5'-DFUR chemoprophylaxis in superficial bladder cancer. Kanagawa Urology 5'-DFUR Study Group 
264 1 |c 2000 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 19.10.2000 
500 |a Date Revised 23.11.2015 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a 5'-Deoxy-5-fluorouridine (5'-DFUR), an oral fluorinated pyrimidine carbamate, is widely used in patients with gastrointestinal and breast cancers because of its effectiveness. However, in bladder cancer, response rates have only been reported in Phase II clinical trials. Therefore, we conducted a prospective randomized trial to investigate chemoprophylactic effect of 5'-DFUR against recurrence of superficial bladder cancer after transurethral bladder tumor resection (TUR-Bt). The subjects were grouped as follows: 1) 5'-DFUR group (n = 31), received 600 mg/day of 5'-DFUR starting 2-3 weeks after TUR-Bt for 2 years; and 2) control group (n = 31) received no 5'-DFUR. Although there was no significant difference between groups, the cumulative recurrence rates was more favorable in the 5'-DFUR group (p = 0.256) than in the controls. Results according to cancer factors showed that, in patients with G2 based on grading, those in the 5'-DFUR group tended to have a lower recurrence rate than the control group (p = 0.070). There was a 40% incidence of adverse drug reactions (12/30 patients), primarily slight gastrointestinal symptoms which disappeared or improved with drug discontinuation. The results of the present study suggest that 5'-DFUR might be the choice of treatment to prevent recurrence of superficial bladder cancer 
650 4 |a Clinical Trial 
650 4 |a English Abstract 
650 4 |a Journal Article 
650 4 |a Multicenter Study 
650 4 |a Randomized Controlled Trial 
650 7 |a Antimetabolites, Antineoplastic  |2 NLM 
650 7 |a Floxuridine  |2 NLM 
650 7 |a 039LU44I5M  |2 NLM 
650 7 |a doxifluridine  |2 NLM 
650 7 |a V1JK16Y2JP  |2 NLM 
700 1 |a Noguchi, S  |e verfasserin  |4 aut 
700 1 |a Masuda, M  |e verfasserin  |4 aut 
700 1 |a Hosaka, M  |e verfasserin  |4 aut 
700 1 |a Noguchi, K  |e verfasserin  |4 aut 
700 1 |a Sasaki, K  |e verfasserin  |4 aut 
700 1 |a Miura, T  |e verfasserin  |4 aut 
700 1 |a Ikeda, I  |e verfasserin  |4 aut 
700 1 |a Kondo, I  |e verfasserin  |4 aut 
700 1 |a Senga, Y  |e verfasserin  |4 aut 
700 1 |a Moriyama, M  |e verfasserin  |4 aut 
700 1 |a Fukushima, S  |e verfasserin  |4 aut 
700 1 |a Ebato, T  |e verfasserin  |4 aut 
700 1 |a Fukuda, M  |e verfasserin  |4 aut 
700 1 |a Kitami, K  |e verfasserin  |4 aut 
700 1 |a Fukuoka, H  |e verfasserin  |4 aut 
700 1 |a Sato, K  |e verfasserin  |4 aut 
700 1 |a Hirokawa, M  |e verfasserin  |4 aut 
700 1 |a Chiba, K  |e verfasserin  |4 aut 
700 1 |a Kanno, H  |e verfasserin  |4 aut 
700 1 |a Miyai, K  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Hinyokika kiyo. Acta urologica Japonica  |d 1962  |g 46(2000), 8 vom: 01. Aug., Seite 525-30  |w (DE-627)NLM012631779  |x 0018-1994  |7 nnns 
773 1 8 |g volume:46  |g year:2000  |g number:8  |g day:01  |g month:08  |g pages:525-30 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_40 
912 |a GBV_ILN_60 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_350 
912 |a GBV_ILN_2001 
912 |a GBV_ILN_2003 
912 |a GBV_ILN_2005 
912 |a GBV_ILN_2006 
912 |a GBV_ILN_2008 
912 |a GBV_ILN_2010 
912 |a GBV_ILN_2012 
912 |a GBV_ILN_2018 
951 |a AR 
952 |d 46  |j 2000  |e 8  |b 01  |c 08  |h 525-30